RxDoctor Payments Data

Kyle Jones, DO

Family Medicine · Tulsa, OKNPI 1164603262

Payments from drug & device makers

$2,379in general payments, 2019–2025

Across 133 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$451
  • Bayer$234
  • Takeda Pharmaceuticals U.S.A., Inc.$215
  • Lilly USA, LLC$165
  • Novo Nordisk$163
  • Amgen$154
  • plus $996 from 15 others

What the payments were for

  • Food & beverage$2,379100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,379 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$69,210
Medicare patients
170
Services billed
1,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide140$158,457
EliquisApixaban141$142,554
MounjaroTirzepatide115$125,676
FarxigaDapagliflozin Propanediol108$96,592
JardianceEmpagliflozin83$83,847
TrulicityDulaglutide68$71,203
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$68,563
JanuviaSitagliptin Phosphate36$40,425
XareltoRivaroxaban48$37,333
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$32,344
MyrbetriqMirabegron52$31,106
EntrestoSacubitril/Valsartan34$30,063
RybelsusSemaglutide16$27,055
Lantus SolostarInsulin Glargine,hum.Rec.Anlog115$17,416
Janumet XrSitagliptin Phos/Metformin Hcl12$15,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$165$196,879183 claims
Novo NordiskOzempic, Rybelsus$163$185,512156 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$451$135,898165 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$136$96,791130 claims
Boehringer IngelheimJardiance, Synjardy Xr$153$93,485100 claims
MerckJanuvia, Janumet Xr$41$55,93148 claims
Johnson & JohnsonXarelto$62$37,33348 claims
NovartisEntresto$76$30,06334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →